Atovaquone‐Statine “Double‐Drugs” with High Antiplasmodial Activity

S. Romeo,S. Parapini,M. Dell’Agli,N. Vaiana,P. Magrone,G. Galli,A. Sparatore,D. Taramelli,E. Bosisio

DOI: https://doi.org/10.1002/cmdc.200700166

IF: 3.54

2008-03-14

ChemMedChem

Abstract:Malaria is one of the most widespread parasitic infections in the world; the unavailability of a vaccine and the spread and intensification of drug resistance over the past 15–20 years have led to a dramatic decline in the efficacy of the most affordable antimalarial drugs. The reported presence of sporadic cases of artemether resistance indicates the need for increased vigilance and a coordinated and rapid deployment of drug combinations. Plasmepsins are a family of proteases comprising aspartic proteases Plasmepsins I, II, and IV (PLM I, PLM II, and PLM IV) and an histoaspartic protease (HAP) localized in the digestive vacuole of Plasmodium falciparum (Pf) together with other proteases (that is, falcipains). These proteases are involved in the degradation of haemoglobin during the intraerythrocytic cycle of Pf. Haemoglobin digestion is a crucial process for the survival of the parasite in the red blood cell (RBC) both for providing amino acids for protein biosynthesis and for reducing the osmotic pressure in the RBC. The inhibition of these enzymes has been proposed as a promising target for the development of a new antimalarial therapeutic approach. The protease machinery developed by the parasite to accomplish this task is quite redundant and the role of each enzyme needs further investigation. The developed PLM inhibitors, including molecules with a statinebased core and peptidomimetic structures, showed a limited effectiveness in inhibiting the intraerythrocytic parasite growth (IC50 range 1–20 mm), although their Ki values against PLMs were in the nanomolar range. Their low potency against cultured parasites may be explained by the redundancy of proteases which implies that the blockade of one or two PLMs may not be lethal. The “double-drug” approach combines two different inhibitors into a single chemical entity by a linker, with the aim of improving the physicochemical characteristics of the individual compounds. We have previously reported the high antiplasmodial activity of double-drug 1, designed by linking a statinebased inhibitor of PLMs, with primaquine, a known antimalarial drug active against the hepatic stage of Plasmodium. 10] We describe herein the synthesis and biological evaluation of a series of ATQ–statine double-drugs. ATQ is a very potent anti-